IM Resident @BCM_InternalMed | CV research alumni @MayoClinicCV @HMethodistCV | Co-creator of @CardioTechx | Opinions represent my own
Joined May 2026
- Tweets78
- Following355
- Followers159
- Likes378
SaharSamimiMD retweeted
Don’t miss #EACVI webinar on how to use #multimodality #imaging during pregnancy and peripartum under @escardio @EACVIPresident with @leylaelifsade @anagalmeida1
Register today : esc365.escardio.org/event/27…
@escardio
@MGBWomenHeart
@MassGenBrigham
🤖 Made with AI
SaharSamimiMD retweeted
Join @CardioNerds in Chicago on 11/7 after #AHA26 for an evening of debates & conversation
🥊 Lifestyle vs Meds+Lifestyle @BrazileTiffany & @JennaSkowronski
🥊 AC vs LAAO @DPipilasMD
Expert commentaries by @EugeniaGianos & @KTamirisaMD
Register: cvent.me/Vg5YRe?rt=doo4_eD0d…
SaharSamimiMD retweeted
Women remain significantly underrepresented in structural heart trial leadership.
Among 88 trials, women held just 7% of committee seats, chaired 12%, and were first or last author on 14%.
Representation in research leadership matters.
tctmd.com/news/women-still-u…
Looking forward to @HMethodistCV’s Multimodality CV Imaging Conference THIS weekend! 🫀
#cardiotwitter #CardioX #cardiology #AI
In only 1wk! interact with world-renown MMI experts: AI in CV Imaging/valvular heart/HCM/Sarcoid/amyloid... Recording available for 2 mo. Priced for global audience:25-50$! tinyurl.com/57k3hmu4
@HMethodistCV @HMHCardioFellow @JACCJournals @SachinGoelMD @escardio @NadeenFaza
SaharSamimiMD retweeted
🫀Excited to share our work, now published in @JSCAI!
❓Do women and men with severe MR experience different delays in reaching the structural heart team?
➡️We looked at referral timing among patients undergoing M-TEER @DeBakeyCVedu 🧵
sciencedirect.com/science/ar…
SaharSamimiMD retweeted
🫀 New in @JAHA_AHA!
Valve-in-valve or valve-in-ring TMVR - how do outcomes differ?
In our pooled analysis of 1,947 patients:
🔹 30-day mortality was similar
🔹 ViV-TMVR → ↓ LVOT obstruction
🔹 ViV-TMVR → ↓ reintervention
🔹 ViV-TMVR → ↓ acute kidney injury
The takeaway? ViV and ViR are not the same procedure - anatomy matters, and thoughtful patient selection and procedural planning are essential.
Very excited to see this work published and grateful to everyone who contributed!
🔗 doi.org/10.1161/JAHA.125.044…
#StructuralHeart #TMVR #MitralValve #CardioTwitter @HMethodistCV @Joe_Aoun_ @SachinGoelMD
SaharSamimiMD retweeted
Today marks the first-ever National Women in Medicine Day in the USA, launched by our partner @WimedicineOrg.
We’re proud to celebrate the women advancing healthcare and creating a more equitable future. Our community is built around this mission.
#WomenInMedicineDay
SaharSamimiMD retweeted
Excellent commentary by Drs. @AndrewOseran and @prihatha on our recent study in @JACCJournals. Beyond the four foundational pillars of HFrEF therapy, they emphasize policy as the critical “fifth pillar”, bridging the gap between what evidence recommends and what patients actually receive. 💊🏛️🫀 @gcfmd @ATSandhu @SJGreene_md @DOM_UCLA @uclaCVfellows @DOM_UCLA
sciencedirect.com/science/ar…
SaharSamimiMD retweeted
🤖 Is AI-powered 3D echocardiography truly automated?
Artificial intelligence is transforming 3D echocardiography, but this editorial reminds us that automation is only as good as the images it receives. Without standardized acquisition and expert oversight, AI may deliver precise-looking—but potentially misleading—results.
🔍 Key messages:
✅ Image quality remains the single most important determinant of AI performance. Automation cannot compensate for poor image acquisition or non-standardized datasets.
✅ AI algorithms may suffer from "silent drift"—maintaining the appearance of accuracy while progressively losing reliability when applied to new scanners, patient populations, or disease phenotypes outside their training domain.
✅ In conditions such as hypertrophic cardiomyopathy, inaccurate automated LVEF measurements could directly influence treatment decisions, highlighting the need for phenotype-specific validation.
✅ The authors propose that AI should function as an expert-supervised assistant, supported by standardized acquisition protocols, quality control, and continuous validation—not as a replacement for clinical expertise.
💡 The future of AI in echocardiography is not about replacing experts—it's about combining high-quality image acquisition with intelligent automation to achieve more reliable and reproducible patient care.
📖 Read the full editorial: doi.org/10.1093/ehjimp/qyag1…
#CardioX #ArtificialIntelligence #Echocardiography #3DE #CardiacImaging #DigitalHealth #PrecisionMedicine #Cardiology #MedTwitter #OpenScience
SaharSamimiMD retweeted
Heart research is advancing, but representation still has catching up to do. ❤️🫀
A study led by BCM resident Dr. Sahar Samimi found women hold just 7% of leadership committee seats in interventional structural heart disease trials.
Read more: medscape.com/viewarticle/wom…
SaharSamimiMD retweeted
Sharing the ONE LINER highlights from all the clinical trials presented at #ESCCongress2026 across all spectrum of cardiology 🫀⭐️! So many outstanding IC trials 🤩Congratulations @escardio for a phenomenal advancement of science to next level! 👏 ♥️ #FIT @ESC_Journals @ACCinTouch @NEJM @JAMACardio @JACCJournals @TCTMD @TheLancet @BeaumontIC @RyanMadderMD @IvanHansonMD @amrabbasmd @SimonDixonMBChB @AhmadJabri8
SaharSamimiMD retweeted
Good summary of A-CLOSE comparing clooidogrel monotherapy to DAPT high ischemic risk patients.
Big lesson: NACE is not a meaningful endpoint when there are tradeoffs.
And unless you're willing to take on mortality risk to avoid minor bleeding, dapt was a lot better.
Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients: @NEJM #ESCCongress2026 #ESCCongress
🥸 The A-CLOSE trial: Plavix vs DAPT
👇👇👇
SaharSamimiMD retweeted
🚨 The 2026 @escardio #HeartFailure Guidelines are here❗️#ESCcongress @secardiologia
1) HFmrEF is gone.
Acute HF is gone.
NT-proBNP cut-offs are now age-adjusted.
Everything that matters 🧵👇
2/ 🔄 NEW DEFINITION — two phenotypes only
❤️🩹 HFrEF → LVEF <50% + symptoms/signs
🫀 HFpEF → LVEF ≥50% + symptoms/signs + objective evidence of structural/functional abnormality
❌ HFmrEF eliminated: same aetiology, same pathophysiology, same treatment response as HFrEF
SaharSamimiMD retweeted
Prospective data shows that in NSTEMI, Queen of Hearts AI-ECG identified a much higher-risk group, with adjusted HR 2.45 for cardiovascular mortality even after GRACE >140.
And unlike GRACE, the result is available immediately from the first ECG. #ESC2026
Excited to see our study featured by @TCTMD!
While structural heart disease treatments advance, trial leadership representation is not keeping pace according to a systematic review revealing that women are still underrepresented in steering committees. bit.ly/4wHhy6i @SaharSamimiMD @MayraGuerreroMD @hvanspall
SaharSamimiMD retweeted
Could a routine mammogram offer another window into women’s heart health?
A study found breast artery calcification was linked to higher cardiovascular risk, including among women classified as low risk by traditional risk scores.
jacc.org/doi/10.1016/j.jacad…
SaharSamimiMD retweeted
Women remain underrepresented in the leadership of interventional structural heart disease trials.
Who leads research shapes whose perspectives are reflected in the evidence. Closing this gap requires creating more pathways for women to lead.
jacc.org/doi/10.1016/j.jacad…
Thank you, @Medscape, for spotlighting the important conversation around women’s representation in structural heart disease trial leadership and why it matters for the evidence we generate.
🔗 medscape.com/viewarticle/wom…
🫀Grateful to see our work on women’s representation in the leadership of interventional structural heart disease trials now published in @JACCJournals, alongside a very thoughtful accompanying editorial by @Drroxmehran, @ditchhaporia and Dr. Puja B. Parikh.
Among 88 high-impact SHD trials, women held just 7% of trial committee positions, with no meaningful improvement over 15 years.
Read more about trends in women’s representation in SHD trial leadership, factors that may contribute to these patterns, and potential opportunities for future improvement here: 🔗jacc.org/doi/10.1016/j.jacad…
Very thankful to my amazing coauthors @KharsaChloe, @mderdem3, @NadeenFaza, and @MayraGuerreroMD, who helped shape this work.
#CardioTwitter #CardioX #StructuralHeart #ACCWIC @ACCinTouch
4/ But two important challenges remain: mild PVL and permanent pacemaker implantation rates were high.
At 30 days:
🔹 Mild PVL: 31.1% Evolut & 19.9% Navitor
p-interaction = 0.046
🔹 New PPI: 13.4% & 15.3%
p-interaction = 0.26
So, while clinically significant PVL is now uncommon, further room for refinement remains, as even mild PVL has been associated with bioprosthetic valve failure and increased all-cause mortality.
7/ Take-home message:
Contemporary self-expanding THVs demonstrate:
✅ High device success
✅ Low early mortality
✅ Favorable hemodynamics through 1 year
✅ Low rates of moderate-or-greater PVL
🚨At the same time, mild PVL and PPI remain important opportunities for continued procedural and device refinement.
What’s next? More granular procedural/anatomic data and longer-term follow-up to better understand durability and reintervention rates.
8/ Huge thank you to all of our co-authors for the incredible work that went into bringing together this contemporary pooled analysis of self-expanding TAVR outcomes, and especially to Dr. @SachinGoelMD for his invaluable mentorship and guidance throughout.
And a special shoutout to @DrShawnShaji, @praeformed, and @RahulSark13, who put an enormous amount of work into this project!
@KharsaChloe @Joe_Aoun_ @SLittleMD @NadeenFaza @SyedZaidMD @WKayaniMD @MReardon19 @n_kleiman @HMethodistCV